New to Pink Sheet?
Start a free trial today!
Register for our free email digests:
Register for our free email digests:
Kedrion S.p.A.
http://www.kedrion.com
Already a Biomedtracker subscriber?
You have access to the full company record through your subscription
Want to become a subscriber?
Subscribers get more company details, updates, company financials and company products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Kedrion S.p.A.
COVID-19 Lessons: Experts Predict Shift Toward Intermittent Hemodialysis In ICUs
The pandemic may accelerate a move toward versatile, single-solution renal replacement therapy in intensive care.
Takeda/Ovid Plan Phase III For Soticlestat In Dravet Syndrome, But Pull Back On LGS
A Phase II trial of the CH24H inhibitor showed a statistically significant benefit in children with the rare epilepsy syndrome Dravet Syndrome, but not in Lennox-Gastaut syndrome (LGS).
IPOs Are Back: Liquid Biopsy, Cardio, Dialysis Firms Lead $1.5Bn Charge
Who wants to go public during a once-in-a-century crisis? It seems like quite a few medtechs do.
UK Orders 450K POC Tests For COVID-19, First Diagnostic From Oxford Nanopore
The LamPORE assay will also be used to test for the winter influenza virus.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
- Other Names / Subsidiaries
-
- Kedrion Biopharma (US)